Latest News

Accentus Medical to Exhibit at Venturefest 2010

23rd June 2010
Accentus Medical, a leading medical technology company which provides advanced coatings and surface treatments for orthopaedic implants, will be exhibiting at Venturefest 2010.

more

Accentus Medical Wins Best Medical Devices and Healthcare Award

4th November 2009
Accentus Medical, a leading medical technology company which provides advanced coatings and surface treatments for orthopaedic implants, has been named as the Winner of the Best Medical Devices and Healthcare Technologies Award at the Martin and Audrey Wood Enterprise Awards 2009.

more

Accentus Medical Wins Major Technology Innovation Award

31st October 2008
Accentus Medical is proud to announce that it has been presented with a major award from the London Technology Fund, London's specialist investor in new technology companies.  At an Awards Ceremony in London on 29th October, the company was declared winner of the Life Sciences sector award, and also the overall Grand Prix.  The winning formula was innovative technology, a clear market need and a strong management team.  The Awards were the culmination of an eight-month programme which started with 150 companies and involved 40 shortlisted companies in a programme of training and advice designed to prepare for investment and build relationships with major technology corporates.

Philip Agg, Chief Executive of Accentus Medical, received the Grand Prix award from Dr David Bott, Director of Innovation Programmes, Technology Strategy Board.  Philip stated: "We are delighted to be sector winners and the overall winner of the Grand Prix, and we are very grateful to the London Technology Fund for the opportunity to participate in this innovative and prestigious competition. The training workshops have been an excellent source of information and knowledge for our management team, providing us with the essential business toolkit as we embark on the exciting journey of growing the company, delivering excellent products to our customers and building value for our investors."

Martin Pickford, Managing Director of Accentus Medical and co-inventor of the company's breakthrough Agluna^® technology, stated: "This award is a tribute to the whole team who have worked so hard in developing the company since its formation in 2001. We are particularly excited about the commercial potential for Agluna^®, an innovative technology utilising the biocidal properties of silver with the aim of reducing the risk of post-operative infection in surgical implants such as joint replacements, pacemakers and dental implants.  This proprietary technology continues to demonstrate very encouraging results in its use with patient specific megaprostheses, manufactured by our licensee Stanmore Implants Worldwide, and is starting to create widespread interest within the orthopaedic and broader medical device industry."

For a full press release from the London Technology Fund, visit the following link:

http://www.londontechnologyfund.com/materials/ltf_competition_press_release_30_october_08.pdf

ENDS

Press Release

25th January 2008

Latest News on Agluna^TM Technology

Accentus Medical has today announced that the number of patients who have received patient-specific tumour mega-prostheses modified with Agluna™ biocidal surface enhancement has now surpassed 30.

These patient-specific prostheses are manufactured and distributed by Stanmore Implants Worldwide Ltd (SIW), with the Agluna™ surface enhancement supplied by SIW under licence from Accentus Medical. The devices have mainly been implanted at the Royal National Orthopaedic Hospital in London and at the Royal Orthopaedic Hospital in Birmingham, although recently patients in mainland Europe have also received Agluna™ modified implants.

The first patient-specific prosthesis utilising the Agluna™ surface modification was implanted in March 2006, and it is hoped to increase the patient cohort to 100 by the end of 2008.

Click here to download  a summary of the types of procedures carried out to date using mega-prostheses treated with Agluna™ technology

 
ENDS

 For further information please contact Kirsten Robinson in the press office on 0845 226 0803.

Press Release

21st November 2007

New technology developed by Accentus Medical presented at ISOLS

On 13 September, at the International Symposium on Limb Salvage (ISOL) in Hamburg Germany, Dr Paul Unwin, CEO and General Manager of Stanmore Implants Worldwide Ltd (SIW), presented to a group of leading European orthopaedic surgeons, a new orthopaedic surface modification technology developed by Accentus Medical.

Utilising a wet chemistry technique, the process developed by the Accentus Medical research and development team led by Managing Director, Dr Martin Pickford, produces a silver biocide surface modification to titanium or titanium alloy implants. 

During laboratory testing the concentration of silver within the surface has been shown to be effective in eliminating many strains of bacteria which are commonly found in orthopaedic patients suffering from post-operative infections.

The new surface technique known as Agluna^TM has been used to date on 18 patients receiving patient-specific custom made tumor implants manufactured by SIW, with encouraging results.

Stanmore Implants approached Accentus Medical in 2002, to create a new surface for their patient-specific mega-prostheses that would help reduce problems of infection.  In March 2006, the first Stanmore Implant patient received the Agluna^TM modified implant.

Click here to download presentation 

ENDS

For further information please contact Kirsten Robinson in the press office on 0845 226 0803.

Press Release

13th July 2007
Accentus Medical and Stanmore Implants present new technology to British Orthopaedic Oncology Society

New orthopaedic technology developed by Accentus Medical and used by Stanmore Implants Worldwide Ltd on patient-specific custom and massive orthopaedic endoprostheses was presented on 6th July to surgeons attending the British Orthopaedic Oncology Society Annual Scientific Meeting in London.

The process developed by the Accentus Medical research and development team, produces a silver biocide surface modification to titanium or titanium alloy implants.  The concentration of silver within the surface has been shown to be effective in eliminating bacteria.

Stanmore Implants approached Accentus Medical in 2002, to create a new surface for their patient-specific mega-prostheses that would help reduce problems of infection.  The new surface technique known as Agluna^TM  has been used in seventeen patients so far with very encouraging results.  Following the presentation, plans are now in preparation with a view to expanding this patient-specific study to all Orthopaedic Oncology centres in the UK.

Click here to download presentation

ENDS

For further information please contact Kirsten Robinson in the press office on 0845 226 0803.